These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2715079)

  • 1. Potentiation of radiation effects on multicellular tumor spheroids (MTS) of HeLa cells by lonidamine.
    Kim JH; Kim SH; He SQ; Alfieri AA; Young CW
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1277-80. PubMed ID: 2715079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of radiation effects on two murine tumors by lonidamine.
    Kim JH; Alfieri AA; Kim SH; Young CW
    Cancer Res; 1986 Mar; 46(3):1120-3. PubMed ID: 3943089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo.
    Kim JH; Kim SH; Alfieri A; Young CW; Silvestrini B
    Oncology; 1984; 41 Suppl 1():30-5. PubMed ID: 6717892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lonidamine and radiotherapy in head and neck cancers. A pilot study.
    Magno L; Terraneo F; Ciottoli GB
    Oncology; 1984; 41 Suppl 1():113-5. PubMed ID: 6717889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of radiation response of prostatic carcinoma by lonidamine.
    Dudak SD; Lopez A; Block NL; Lokeshwar BL
    Anticancer Res; 1996; 16(6B):3665-71. PubMed ID: 9042239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combined use of radiation therapy and lonidamine in the treatment of brain metastases.
    DeAngelis LM; Currie VE; Kim JH; Krol G; O'Hehir MA; Farag FM; Young CW; Posner JB
    J Neurooncol; 1989 Sep; 7(3):241-7. PubMed ID: 2677257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft.
    Pratesi G; De Cesare M; Zunino F
    Cancer Chemother Pharmacol; 1996; 38(2):123-8. PubMed ID: 8616901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization of Meth-A fibrosarcoma in mice by Lonidamine.
    Kim JH; Alfieri A; Kim SH; Young CW; Silvestrini B
    Oncology; 1984; 41 Suppl 1():36-8. PubMed ID: 6717893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lonidamine, a new approach to cancer therapy.
    Caputo A; Silvestrini B
    Oncology; 1984; 41 Suppl 1():2-6. PubMed ID: 6371644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of tumor cell sensitivity to antineoplastic agents lonidamine and bouvardin (NSC 259968) at elevated temperatures.
    Adwankar MK; Chitnis MP
    Neoplasma; 1986; 33(2):217-23. PubMed ID: 3713924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer.
    Scarantino CW; McCunniff AJ; Evans G; Young CW; Paggiarino DA
    Int J Radiat Oncol Biol Phys; 1994 Jul; 29(5):999-1004. PubMed ID: 8083102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological damage induced in vivo by Lonidamine on human metastatic cancer cells.
    De Martino C; Battelli T; Cavaliere R; Gallo Curcio C; Bellocci M; Manocchi D; Giustini L; Mattioli R; Rinaldi M; Di Filippo F
    Oncology; 1984; 41 Suppl 1():94-103. PubMed ID: 6717904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
    Ning SC; Hahn GM
    Cancer Res; 1990 Dec; 50(24):7867-70. PubMed ID: 2253227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.
    Silvestrini B; Hahn GM; Cioli V; De Martino C
    Br J Cancer; 1983 Feb; 47(2):221-31. PubMed ID: 6824568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I toxicologic study of Lonidamine in cancer patients.
    Band PR; Deschamps M; Besner JG; Leclaire R; Gervais P; De Sanctis A
    Oncology; 1984; 41 Suppl 1():56-9. PubMed ID: 6717896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
    Ning SC; Hahn GM
    Cancer Res; 1991 Nov; 51(21):5910-4. PubMed ID: 1718588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lonidamine alone and in combination with other chemotherapeutic agents in the treatment of cancer patients.
    Pacilio G; Carteni G; Biglietto M; De Cesare M
    Oncology; 1984; 41 Suppl 1():108-12. PubMed ID: 6326014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of Lonidamine in patients with advanced malignancy.
    Evans WK; Shepherd FA; Mullis B
    Oncology; 1984; 41 Suppl 1():69-77. PubMed ID: 6717899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer.
    Magno L; Terraneo F; Bertoni F; Tordiglione M; Bardelli D; Rosignoli MT; Ciottoli GB
    Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):45-55. PubMed ID: 8175445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lonidamine and hyperthermia: clinical experience in melanoma. Preliminary results.
    Cavaliere R; Di Filippo F; Varanese A; Carlini S; Calabro A; Aloe L; Piarulli L
    Oncology; 1984; 41 Suppl 1():116-20. PubMed ID: 6717890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.